Reported about 7 hours ago
AstraZeneca has paused its planned £200 million investment in its Cambridge research site, which was expected to create 1,000 jobs. This follows a trend of pharmaceutical companies pulling back from the UK due to a challenging business environment, as evidenced by Merck's recent decision to abandon a new research center in London. AstraZeneca's CEO has called for improvements in the business climate to encourage investment, highlighting increasing concerns about the UK's viability as a location for pharmaceutical investments.
Source: YAHOO